BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 34774243)

  • 1. Hypercalcemia of Malignancy.
    Hu MI
    Endocrinol Metab Clin North Am; 2021 Dec; 50(4):721-728. PubMed ID: 34774243
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment of Hypercalcemia of Malignancy.
    Chakhtoura M; El-Hajj Fuleihan G
    Endocrinol Metab Clin North Am; 2021 Dec; 50(4):781-792. PubMed ID: 34774248
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Bone and calcium metabolism associated with malignancy. Malignancy-associated hypercalcemia.].
    Tai N; Inoue D
    Clin Calcium; 2018; 28(11):1503-1508. PubMed ID: 30374007
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Denosumab: a new agent in the management of hypercalcemia of malignancy.
    Thosani S; Hu MI
    Future Oncol; 2015; 11(21):2865-71. PubMed ID: 26403973
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment of hypercalcaemia of malignancy in adults.
    Mc Donald D; Drake MT; Crowley RK
    Clin Med (Lond); 2023 Sep; 23(5):503-507. PubMed ID: 37775175
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment of Hypercalcemia of Malignancy in Adults: An Endocrine Society Clinical Practice Guideline.
    El-Hajj Fuleihan G; Clines GA; Hu MI; Marcocci C; Murad MH; Piggott T; Van Poznak C; Wu JY; Drake MT
    J Clin Endocrinol Metab; 2023 Feb; 108(3):507-528. PubMed ID: 36545746
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Denosumab for treatment of hypercalcemia of malignancy.
    Hu MI; Glezerman IG; Leboulleux S; Insogna K; Gucalp R; Misiorowski W; Yu B; Zorsky P; Tosi D; Bessudo A; Jaccard A; Tonini G; Ying W; Braun A; Jain RK
    J Clin Endocrinol Metab; 2014 Sep; 99(9):3144-52. PubMed ID: 24915117
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Calcitriol Elevation Is Associated with a Higher Risk of Refractory Hypercalcemia of Malignancy in Solid Tumors.
    Chukir T; Liu Y; Hoffman K; Bilezikian JP; Farooki A
    J Clin Endocrinol Metab; 2020 Apr; 105(4):e1115-23. PubMed ID: 31841590
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Denosumab in hypercalcemia of malignancy: a case series.
    Dietzek A; Connelly K; Cotugno M; Bartel S; McDonnell AM
    J Oncol Pharm Pract; 2015 Apr; 21(2):143-7. PubMed ID: 24415364
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Randomized, double-blind, phase II trial of gallium nitrate compared with pamidronate for acute control of cancer-related hypercalcemia.
    Cvitkovic F; Armand JP; Tubiana-Hulin M; Rossi JF; Warrell RP
    Cancer J; 2006; 12(1):47-53. PubMed ID: 16613662
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Treatment of malignancy associated hypercalcemia].
    Tai N; Inoue D
    Clin Calcium; 2014 Aug; 24(8):1223-8. PubMed ID: 25065875
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hypercalcemia of malignancy remains a clinically relevant problem.
    Van Poznak C
    Cancer J; 2006; 12(1):21-3. PubMed ID: 16613658
    [No Abstract]   [Full Text] [Related]  

  • 13. Denosumab for patients with persistent or relapsed hypercalcemia of malignancy despite recent bisphosphonate treatment.
    Hu MI; Glezerman I; Leboulleux S; Insogna K; Gucalp R; Misiorowski W; Yu B; Ying W; Jain RK
    J Natl Cancer Inst; 2013 Sep; 105(18):1417-20. PubMed ID: 23990665
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The management of hypercalcemia of malignancy.
    Harvey HA
    Support Care Cancer; 1995 Mar; 3(2):123-9. PubMed ID: 7773580
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Humoral Hypercalcemia in a Patient with Cholangiocellular Carcinoma - Effective Therapy with Denosumab.
    Harsch IA; Konturek PC
    Am J Case Rep; 2019 Sep; 20():1325-1330. PubMed ID: 31492829
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Refractory hypercalcemia of malignancy: a problem with many potential roots.
    Farooki A
    Front Endocrinol (Lausanne); 2023; 14():1088984. PubMed ID: 37265703
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mechanisms and treatment of hypercalcemia of malignancy.
    Clines GA
    Curr Opin Endocrinol Diabetes Obes; 2011 Dec; 18(6):339-46. PubMed ID: 21897221
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Progress in therapy and diagnosis: Hypercalcemia due to parathyroid hormone-related protein producing neoplasms].
    Tanaka Y; Okada Y
    Nihon Naika Gakkai Zasshi; 2007 Apr; 96(4):669-74. PubMed ID: 17506302
    [No Abstract]   [Full Text] [Related]  

  • 19. Denosumab is Effective for Controlling Serum Calcium Levels in Patients with Humoral Hypercalcemia of Malignancy Syndrome: A Case Report on Parathyroid Hormone-related Protein-producing Cholangiocarcinoma.
    Ashihara N; Nakajima K; Nakamura Y; Kobayashi M; Shirahata K; Maeda C; Uehara T; Gomi D; Ito N
    Intern Med; 2016; 55(23):3453-3457. PubMed ID: 27904108
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Onco-nephrology: the pathophysiology and treatment of malignancy-associated hypercalcemia.
    Rosner MH; Dalkin AC
    Clin J Am Soc Nephrol; 2012 Oct; 7(10):1722-9. PubMed ID: 22879438
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.